<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Sutro Biopharma — News on 6ix</title>
<link>https://6ix.com/company/sutro-biopharma</link>
<description>Latest news and press releases for Sutro Biopharma on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Sun, 19 Apr 2026 23:45:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/sutro-biopharma" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c58678dffbe2df11aa68.webp</url>
<title>Sutro Biopharma</title>
<link>https://6ix.com/company/sutro-biopharma</link>
</image>
<item>
<title>Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026</title>
<link>https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-presents-promising-preclinical-data-across-its-pipeline-of-next-generation-single-and-dual-payload-adc-programs-at-aacr-2026</link>
<guid isPermaLink="true">https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-presents-promising-preclinical-data-across-its-pipeline-of-next-generation-single-and-dual-payload-adc-programs-at-aacr-2026</guid>
<pubDate>Sun, 19 Apr 2026 23:45:00 GMT</pubDate>
<description>STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs STRO-006 and STRO-227 show meaningful, dose-dependent antitumor activity across solid tumor models Presentation of TROP2-targeted immunostimulatory ADC program partnered with Astellas highlights the potential of Sutro’s platform for developing dual-payload ADCs SOUTH SAN FRANCISCO, Calif., April 19, 2026 (GLOBE NEWSWIRE) -- Sutro Biopha</description>
</item>
<item>
<title>Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-reports-full-year-2025-financial-results-and-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-reports-full-year-2025-financial-results-and-business-highlights</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 – –</description>
</item>
<item>
<title>Sutro Biopharma Announces Participation at the 16th World ADC London Summit</title>
<link>https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-announces-participation-at-the-16th-world-adc-london-summit</link>
<guid isPermaLink="true">https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-announces-participation-at-the-16th-world-adc-london-summit</guid>
<pubDate>Mon, 23 Feb 2026 13:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced its participation at the 16th World ADC London Summit, taking place in London, UK, February 23-26, 2026. Plenary/Panel Discussion Details: Panel Discussion: ADC Licensing, Partnering & Investment Session Sutro Participant: Hans-Peter Gerber, Ph.D.Date</description>
</item>
<item>
<title>Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering</title>
<link>https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-announces-pricing-110-120000081</link>
<guid isPermaLink="true">https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-announces-pricing-110-120000081</guid>
<pubDate>Tue, 10 Feb 2026 12:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (Nasdaq: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the pricing of an underwritten offering of 7,868,383 shares of its common stock at a price of $13.98 per share. The gross proceeds from this offering are expected to be approximately $110.0 million, before deducting underwriting discounts and commissi</description>
</item>
<item>
<title>Sutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-present-44th-annual-210500834</link>
<guid isPermaLink="true">https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-present-44th-annual-210500834</guid>
<pubDate>Wed, 07 Jan 2026 21:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Jane Chung, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 11:15 AM PT / 2:15 PM ET in San Francisco, CA. A live webcast of the presentation will be accessible through</description>
</item>
<item>
<title>Sutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement</title>
<link>https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-regains-compliance-nasdaq-210500678</link>
<guid isPermaLink="true">https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-regains-compliance-nasdaq-210500678</guid>
<pubDate>Wed, 17 Dec 2025 21:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced it has regained compliance with the Nasdaq Stock Market (Nasdaq) continued listing standard for minimum share price under Rule 5450(a)(1) of the Nasdaq Listing Qualifications. On December 17, 2025, the Company received confirmation from the Listing Qu</description>
</item>
<item>
<title>Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-announces-inducement-grants-210500144</link>
<guid isPermaLink="true">https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-announces-inducement-grants-210500144</guid>
<pubDate>Tue, 16 Dec 2025 21:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that on December 15, 2025, the Compensation Committee of Sutro’s Board of Directors granted stock options to purchase 24,500 shares of Sutro common stock and 2,000 restricted stock units (RSUs) to new non-executive employees. The grants were made as a</description>
</item>
<item>
<title>Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors</title>
<link>https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-announces-first-cohort-130000851</link>
<guid isPermaLink="true">https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-announces-first-cohort-130000851</guid>
<pubDate>Wed, 03 Dec 2025 13:00:00 GMT</pubDate>
<description>– Initial clinical data expected mid-2026 – SOUTH SAN FRANCISCO, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the patients in the first cohort have been dosed in its Phase 1 trial evaluating STRO-004 in a range of Tissue Factor (TF) expressing solid tumors. STRO-004 is the Company’s TF-targeting exatecan ADC en</description>
</item>
<item>
<title>Sutro Biopharma Announces 1-for-10 Reverse Stock Split</title>
<link>https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-announces-1-10-130000399</link>
<guid isPermaLink="true">https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-announces-1-10-130000399</guid>
<pubDate>Mon, 01 Dec 2025 13:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that its Board of Directors (Board) has approved a reverse stock split of the Company’s outstanding shares of common stock at a ratio of 1-for-10. The reverse stock split will become effective at 12:01 a.m. Eastern Time on December 3, 2025. Sutro’s co</description>
</item>
<item>
<title>Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day</title>
<link>https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-highlights-next-generation-150000498</link>
<guid isPermaLink="true">https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-highlights-next-generation-150000498</guid>
<pubDate>Wed, 12 Nov 2025 15:00:00 GMT</pubDate>
<description>- Company has initiated Phase 1 study with STRO-004, its potential best-in-class Tissue Factor ADC - - Sutro has selected PTK7 as the target for its initial dual-payload candidate, STRO-227 - - Investor webcast today at 7:00AM PT / 10:00AM ET - SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), is hosting a virtual R</description>
</item>
<item>
<title>Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-reports-third-quarter-213000474</link>
<guid isPermaLink="true">https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-reports-third-quarter-213000474</guid>
<pubDate>Thu, 06 Nov 2025 21:30:00 GMT</pubDate>
<description>– Company announces U.S. FDA clearance of Investigational New Drug (IND) application for STRO-004, its potential best-in-class Tissue Factor ADC; Expects to dose first patient before year-end – – Company presented new preclinical data at World ADC and SITC, highlighting novel dual-payload ADCs designed to overcome resistance and delay progression – – Company to host a virtual R&D Day on Wednesday, November 12, 2025 at 10:00AM ET – – Cash, cash equivalents and marketable securities as of Septembe</description>
</item>
<item>
<title>Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025</title>
<link>https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-host-virtual-research-210500974</link>
<guid isPermaLink="true">https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-host-virtual-research-210500974</guid>
<pubDate>Wed, 05 Nov 2025 21:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host a virtual Research & Development Day, highlighting the details of its platform innovation and next-generation ADC pipeline. The live webcast will be held on Wednesday, November 12, 2025, starting at 7:00AM PT / 10:00AM ET. Webcast Information:To a</description>
</item>
<item>
<title>Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference</title>
<link>https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-announces-participation-16th-130000328</link>
<guid isPermaLink="true">https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-announces-participation-16th-130000328</guid>
<pubDate>Mon, 03 Nov 2025 13:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced its participation at the 16th Annual World ADC Conference, taking place in San Diego, November 3-6, 2025. “We look forward to presenting new preclinical data at this year’s World ADC conference that underscore the breadth of innovation emerging from Sutro’s platfor</description>
</item>
<item>
<title>Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones</title>
<link>https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-announces-operational-restructuring-210500832</link>
<guid isPermaLink="true">https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-announces-operational-restructuring-210500832</guid>
<pubDate>Mon, 29 Sep 2025 21:05:00 GMT</pubDate>
<description>– Extends cash runway into at least mid-2027 – SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced an organizational restructuring to prioritize the advancement of its three ADC programs and research and development collaborations. The restructuring, along with certain expected near-term milestone payments, is expe</description>
</item>
<item>
<title>Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-reports-second-quarter-203000430</link>
<guid isPermaLink="true">https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-reports-second-quarter-203000430</guid>
<pubDate>Thu, 07 Aug 2025 20:30:00 GMT</pubDate>
<description>– On track to initiate FIH study with STRO-004, potential best-in-class Tissue Factor ADC, in the second half of 2025 – – Expanded breadth of preclinical data across pipeline, including STRO-006 and dual-payload ADCs – – Entered research collaboration with the FDA to advance regulatory standards for ADCs – – Industry veteran Greg Chow appointed as Chief Financial Officer – – Cash, cash equivalents and marketable securities as of June 30, 2025 of $205.1 million, with cash runway into early 2027 –</description>
</item>
<item>
<title>Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug Conjugates</title>
<link>https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-announces-research-collaboration-120000595</link>
<guid isPermaLink="true">https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-announces-research-collaboration-120000595</guid>
<pubDate>Tue, 22 Jul 2025 12:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it has entered into a collaboration with the U.S. Food and Drug Administration (FDA) to develop reference materials to improve regulatory standards and enhance analytical methods for ADC drug development. The collaboration will leverage Sutro’s cell-free Xpres</description>
</item>
<item>
<title>Sutro Biopharma Appoints Greg Chow as Chief Financial Officer</title>
<link>https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-appoints-greg-chow-120000623</link>
<guid isPermaLink="true">https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-appoints-greg-chow-120000623</guid>
<pubDate>Mon, 02 Jun 2025 12:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Greg Chow as Chief Financial Officer (CFO), effective June 2, 2025. Mr. Chow brings over 25 years of executive leadership experience across corporate finance, capital markets, investment banking, financial accounting, and drug development operati</description>
</item>
<item>
<title>Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-reports-first-quarter-203100581</link>
<guid isPermaLink="true">https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-reports-first-quarter-203100581</guid>
<pubDate>Thu, 08 May 2025 20:31:00 GMT</pubDate>
<description>- Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization - - Promising preclinical results with STRO-004 and dual-payload ADC, as well as STRO-006 programs presented at AACR 2025 and PEGS, respectively - - Three INDs for wholly-owned programs anticipated in next 3 years, beginning with potential best-in-class Tissue Factor ADC, STRO-004, planned for 2H 2025 - - IND-enabling toxicology study ongoing for one program within A</description>
</item>
<item>
<title>Sutro Biopharma to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-participate-upcoming-investor-200500447</link>
<guid isPermaLink="true">https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-participate-upcoming-investor-200500447</guid>
<pubDate>Thu, 01 May 2025 20:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in two upcoming investor conferences. Conference Details: The Citizens Life Sciences ConferenceDate: May 7-8, 2025Location: New York, NY BofA Securities 2025 Health Care ConferenceDate: May 13-15, 2025Location: Las Vegas, NV Webcasts</description>
</item>
<item>
<title>Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025</title>
<link>https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-highlight-next-generation-200500629</link>
<guid isPermaLink="true">https://6ix.com/company/sutro-biopharma/news/sutro-biopharma-highlight-next-generation-200500629</guid>
<pubDate>Mon, 28 Apr 2025 20:05:00 GMT</pubDate>
<description>- Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile -SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced poster presentations at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30 in Chicago, IL. The presentations</description>
</item>
</channel>
</rss>